Again, a High Mortality with Depression and RA
Last week we reported on a Korean study showing a 66% elevated mortality risk in RA patients (n=38,487) with depression.
Last week we reported on a Korean study showing a 66% elevated mortality risk in RA patients (n=38,487) with depression.
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui.
Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics.
A follow-up analysis of a randomized clinical trial found that the use of calcium and vitamin D supplements among postmenopausal women was associated with decreased risk for cancer mortality, but increased risk for cardiovascular disease (CVD) mortality.
A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).
The CDC has updated its Lyme disease surveillance report based on a new case definition. Compared to 2017–2019, the number of cases in 2022 rose by 69%.
A Korean nationwide cohort study found that both seropositive and seronegative rheumatoid arthritis (RA) patients have a significantly higher risk of depression.
While it is believed that autoimmunity follows autoantibody positivity, a Danish study shows the incidence of polyautoimmunity to be similar in rheumatoid arthritis (RA) patients who are either anticyclic citrullinated peptide antibody (ACPA)–positive or ACPA–negative.
According to the National Health Interview Survey (NHIS), in 2022, the prevalence of diagnosed arthritis in adults was 18.9% (women 21.5%, more than men 16.1%). These numbers are down since the CDC's MMWR report of 2019–2021, where is was estimated 21.2% of U.S.
Data from the Global Burden of Diseases Study 2019, suggests that early-onset osteoarthritis (OA) (before age 55 yrs) is an emerging health issue that parallels societal problems of obesity.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.